Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies

NCT07419841 is registered in ClinicalTrials.gov with Compass Therapeutics as lead sponsor.

NCT NCT07419841
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07419841 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-10726 in Patients With Advanced Malignancies
Lead sponsor
Compass Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
May 28, 2026
Completion date
November 1, 2028
Enrollment
70 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial cancer, gastroesophageal cancer (gc), hepatocellular carcinoma (hcc), renal cell carcinoma (rcc)